Potential of pyrazolooxadiazinone derivatives as serine protease inhibitors

被引:7
|
作者
Vicentini, CB
Guarneri, M
Andrisano, V
Guccione, S
Langer, T
Marschhofer, R
Chabin, R
Edison, AM
Huang, X
Knight, WB
Giori, P
机构
[1] Univ Catania, Dipartimento Sci Farmaceut, I-95125 Catania, Italy
[2] Univ Ferrara, Dipartimento Sci Farmaceut, Ferrara, Italy
[3] Univ Bologna, Dipartimento Sci Farmaceut, Bologna, Italy
[4] Univ Innsbruck, Inst Pharmazeut Chem, A-6020 Innsbruck, Austria
[5] Merck Sharp & Dohme Res Labs, Dept Enzymol, Rahway, NJ 07065 USA
[6] Glaxo Wellcome Inc, Dept Enzymol, Res Triangle Pk, NC 27709 USA
来源
JOURNAL OF ENZYME INHIBITION | 2001年 / 16卷 / 01期
关键词
pyrazolo[4,3-c][1,2,5]oxadiazin-3(5H)-ones; mechanism-based inhibitors; serine proteases; flexX docking;
D O I
10.1080/14756360109162352
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
As a part of an investigation on molecular hybrids as new serine protease inhibitors, the pyrazolo [4,3-c][1,2,5]oxadiazin-3(5H)-one ring system was selected as a model of potential mechanism-based inhibitors. Due to the inherent reactivity of this system an optimal balance between susceptibility to nucleophilic attack and stability in solvents was sought prior to development as therapeutic agents. Substitutions on N5 and C7 of the supporting pyrazole ring with either aliphatic or aromatic groups (compounds 2 a-m) and the replacement of the carbonyl oxygen on the reactive oxadiazinone ring with sulfur (compounds 3a,i) were explored. Two members (2i and 2k) of this class of inhibitors displayed time-dependent inhibition of HLE suggesting mechanism-based inhibition. The observation that HLE generated a product(s) from compound 2i which displayed an identical UV-Visible spectrum to that observed during non-enzymatic hydrolysis further supports this proposal. FlexX-based docking of these compounds into a model of the human leukocyte elastase (HLE) active site produced a molecular model of the inhibitor-enzyme interaction.
引用
收藏
页码:15 / +
页数:22
相关论文
共 50 条
  • [32] Serpins and other serine protease inhibitors - Comment
    Patston, PA
    IMMUNOLOGY TODAY, 2000, 21 (07): : 354 - +
  • [33] DESIGN STRATEGIES FOR SERINE-PROTEASE INHIBITORS
    RIPKA, WC
    FASEB JOURNAL, 1995, 9 (06): : A1253 - A1253
  • [34] CLONING AND ANTIGENIC DETERMINANTS OF SERINE PROTEASE INHIBITORS
    WACHTER, A
    PERRIN, P
    SCHECHTER, N
    KAHN, S
    ZWEIMAN, B
    RUBIN, H
    PHILLIPS, SM
    ANNALS OF ALLERGY, 1987, 58 (04): : 294 - 294
  • [35] Neutral inhibitors of the serine protease factor Xa
    Shrader, WD
    Young, WB
    Sprengeler, PA
    Sangalang, JC
    Elrod, K
    Carr, G
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) : 1801 - 1804
  • [36] Recent Advances in Coagulation Serine Protease Inhibitors
    Smallheer, Joanne M.
    Quan, Mimi L.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44, 2009, 44 : 189 - 208
  • [37] Serine protease inhibitors and cytotoxic T lymphocytes
    Ashton-Rickardt, Philip G.
    IMMUNOLOGICAL REVIEWS, 2010, 235 : 147 - 158
  • [38] Editorial: Serine protease inhibitors and their therapeutic applications
    Crocetti, Letizia
    Quinn, Mark T.
    Cilibrizzi, Agostino
    Giovannoni, Maria Paola
    FRONTIERS IN CHEMISTRY, 2022, 10
  • [39] Microbial serine protease inhibitors and their therapeutic applications
    Harish, B. S.
    Uppuluri, Kiran Babu
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 107 : 1373 - 1387
  • [40] Selective inhibitors of the herpesvirus serine protease assemblin
    Flynn, DL
    Becker, DP
    Hippenmeyer, P
    Hockerman, S
    Houseman, K
    Moormann, A
    Rankin, A
    Williams, K
    Wittwer, A
    Zablocki, J
    Wiegand, R
    Holwerda, B
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 241 - MEDI